A Phase I Clinical Study to Evaluate the Safety Tolerability and Preliminary Efficacy of SG2918 in Subjects With Advanced Malignant Tumors
Latest Information Update: 18 Jul 2024
At a glance
- Drugs SG 2918 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Hangzhou Sumgen Biotech
- 14 Dec 2023 New trial record